RxSight (RXST) Common Equity (2020 - 2026)

RxSight (RXST) has reported Common Equity for 7 consecutive years, with $263.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 5.28% year-over-year to $263.3 million; the trailing twelve-month figure through Jun 2026 stood at $263.3 million (down 5.28% YoY), and the FY2025 full-year result was $275.7 million, down 1.98% from the prior year.
• Common Equity declined to $263.3 million in Q2 2026 per RXST's latest filing, from $267.3 million in the prior quarter.
• Across five years, Common Equity topped out at $281.2 million in Q4 2024 and bottomed at $89.9 million in Q4 2022.
• Historically, Common Equity has averaged $204.5 million across 5 years, with a median of $213.6 million in 2024.
• The widest YoY moves for Common Equity: up 140.8% in 2022, down 36.41% in 2022.
• Over 5 years, Common Equity stood at $89.9 million in 2022, then soared by 78.37% to $160.4 million in 2023, then soared by 75.38% to $281.2 million in 2024, then fell by 1.98% to $275.7 million in 2025, then retreated by 4.48% to $263.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $263.3 million, $267.3 million, and $275.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.